Steroid receptor expression in endometria from women treated with tamoxifen

Gynecologic Oncology

Volumn 70, Issue 2, 1998, Pages 188-191

  Kommoss, Friedrich ^a   Karck, Ulrich ^b   Prömpeler, Heiner ^b   Pfisterer, Jacobus ^c   Kirkpatrick, Charles James ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; POSTMENOPAUSE; PRIORITY JOURNAL; SECOND CANCER;

EID: 0032143435     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5087     Document Type: Article

References (25)

1. Rose C, Thorpe S M, Andersen K W. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high estrogen receptor levels. Lancet. 1:1985;16-19.
2. Boccardo F, Bruzzi P, Rugagotti A. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology. 38:1981;281-285.
3. Dilts P V Jr, Hopkins M, Chang A. Rapid growth of leiomyoma in patients receiving tamoxifen. Am J Obstet Gynecol. 166:1992;167-168.
4. Kang J, Baxi L, Heller D. Tamoxifen-induced growth of leiomyomas. J Reprod Med. 41:1996;119-120.
5. Buckley C J. Tamoxifen and endometriosis: case report. Br J Obstet Gynaecol. 97:1990;645-646.
6. Hajjar L RK, Wooshin G H, Nolan S. Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: report of a case. Obstet Gynecol. 82:1993;642-644.
7. Fuith L C, Pflanzl W. Endometriose unter Tamoxifentherapie. Geburtsh Frauenheilk. 55:1995;354-355.
8. Lahti E, Blanco G, Kauppila A. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 81:1993;660-664.
9. Fornander T, Rutquist L E, Cedermark B. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. i:1989;117-120.
10. De Muylder X, Neven P, De Somer Y. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Obstet. 36:1990;127-130.
11. Andersson M, Storm H H, Mouridsen H T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst. 83:1991;1013-1017.
12. Neven P. Tamoxifen and endometrial lesions. Lancet. 342:1993;452.
13. Remmele W, Stegner H E. Immunhistochemischer Nachweis von Östrogenrezeptoren (ER-ICA) in Mammakarzinomgewebe: Vorschlag zur einheitlichen Formulierung des Untersuchungsbefundes. Deutsches Ärtzeblatt. 83:1986;3362-3364.
14. Kommoss F, Pfisterer J, Thome M. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol. 47:1992;317-322.
15. Kommoss F, Pfisterer J, Idris T. Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. Anal Quant Cytol Histol. 16:1994;203-210.
16. Dallenbach-Hellweg G, Hahn U. Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol Pathol. 14:1995;7-15.
17. Gal D, Kopel S, Bashevkin M. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer - preliminary report. Gynecol Oncol. 42:1991;120-123.
18. Gottardis M M, Robinson S P, Satyaswaroop P S. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48:1988;812-815.
19. Anzai Y, Holinka C F, Kuramoto H. Stimulatory effects of 4-hydroxy tamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res. 49:1989;2362-2365.
20. Janne O, Kontula K, Luukainen T, Vihko R. Oestrogen induced progesterone receptor in human uterus. J Steroid Biochem. 6:1975;501-509.
21. Magriples U, Naftolin F, Schwartz P E. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 11:1993;485-490.
22. Barakat R R, Wong G, Curtin J P. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 55:1994;164-168.
23. Powles T J. Status of antiestrogen breast cancer prevention trials. Oncology (Hunting+). 12:1998;28-31.
24. Grainger D J, Metcalfe J C. Tamoxifen: teaching an old drug new tricks. Nature Medicine. 2:1996;381-385.
25. Cuenca R E, Giachino J, Arrendondo M A. Endometrial carcinoma associated with breast cancer. Cancer. 77:1996;2058-2063.